Aurobindo Pharma receives USFDA approval for Zolmitriptan Tablets

13 May 2016 Evaluate

Aurobindo Pharma has received final approval from the US Food & Drug Administration (USFDA) to manufacture and market Zolmitriptan Tablets, 2.5 mg and 5 mg. This product is expected to be launched in Q2 FY16-17. The approved ANDA is bioequivalent and therapeutically equivalent to the reference listed drug product (RID) Zomig Tablets, 2.5 mg and 5 mg tablets, of IPR Pharmaceuticals, Inc.

Zolmitriptan Tablets is used in the acute treatment of migraine with or without aura in adults. The approved product has an estimated market size of $ 46.7 million for the twelve months ending March 2016 according to IMS.

This is the 76th ANDA (including 16 tentative approvals) to be approved out of Unit VII formulation facility in Hyderabad, India for manufacturing Oral Non-Antibiotic products. Aurobindo now has a total of 260 ANDA approvals (223 Final approvals including 11 from Aurolife Pharma LLC and 37 tentative approvals) from USFDA.

Aurobindo Pharma Share Price

1173.15 -8.05 (-0.68%)
01-Jan-2026 09:43 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1712.00
Dr. Reddys Lab 1253.30
Cipla 1501.30
Zydus Lifesciences 909.00
Lupin 2092.90
View more..
Register Now to get our Free Newsletter & much more!

© 2026 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×